Melanoma of skin, malignant (ICD10 C43): combined sexes
Five-year relative survival by diagnosis year and age at diagnosis
|
Five-year relative survival (with 95% confidence interval) by diagnosis year |
EUROCARE-4 |
EUROCARE-4 |
||||||||||
|
Age at diagnosis |
1994-97 |
1998-2002 |
2003-2007 |
2007-2009 |
##2000-2002 |
##2000-2002 |
||||||
|
cohort |
cohort |
cohort |
*hybrid |
Ireland |
Europe average |
|||||||
|
all 15-99 |
83.6% |
85.4% |
86.6% |
86.5% |
||||||||
|
(unstandardized) |
(80.8-86.1%) |
(83.2-87.4%) |
(84.1-88.8%) |
(84.0-88.6%) |
||||||||
|
all 15-99 |
82.9% |
85.3% |
86.0% |
86.0% |
85.9% |
86.1% |
||||||
|
(age-standardized)# |
(76.9-88.1%) |
(80.5-89.4%) |
(80.5-90.5%) |
(80.7-90.4%) |
(83.1-88.8%) |
(84.3-88.0%) |
||||||
|
15-44 |
86.9% |
89.2% |
91.4% |
91.9% |
||||||||
|
(83.0-90.0%) |
(86.3-91.5%) |
(88.4-93.5%) |
(88.8-94.2%) |
|||||||||
|
45-54 |
85.7% |
83.4% |
85.7% |
86.7% |
||||||||
|
(80.3-89.8%) |
(78.9-87.1%) |
(80.1-89.9%) |
(81.5-90.5%) |
|||||||||
|
55-64 |
80.4% |
81.6% |
85.2% |
84.7% |
||||||||
|
(74.2-85.4%) |
(76.9-85.5%) |
(80.0-89.3%) |
(79.6-88.8%) |
|||||||||
|
65-74 |
76.7% |
86.3% |
82.0% |
81.5% |
||||||||
|
(69.8-82.9%) |
(81.0-90.9%) |
(75.4-87.6%) |
(75.2-86.8%) |
|||||||||
|
75-99 |
84.4% |
83.6% |
82.4% |
81.8% |
||||||||
|
(74.8-93.5%) |
(75.4-91.5%) |
(72.9-91.3%) |
(72.9-90.2%) |
|||||||||
|
Footnotes: |
|
|
*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period, |
|
|
supplemented by follow-up 2005-2009 for cases diagnosed in 2005-2006 (to provide more reliable estimation of the first two years of survival). |
|
|
In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data. |
|
|
# Age-standardized figures use the standard patient population proposed for this cancer by: |
|
|
Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316. |
|
|
(Population weights = age 15-44 x28000, 45-54 x17000, 55-64 x21000, 65-74 x20000, 75-99 x14000) |
|
|
## For comparison, the age-standardized average survival (2000-2002) is quoted for countries (including Ireland) that participated in the EUROCARE-4 study: |
|
|
Verdecchia A., Francisci S., Brenner H., et al. 2007. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796. |
|
|
Exclusions (as in EUROCARE): |
|
|
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient |
|
|
(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour. |
|
|
© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients |
|